South Korea-based startup Noul Co. has signed an agreement with The RIGHT Foundation to conduct a global clinical studies to determine the potential for public market access in malaria-endemic countries of Africa and Asia.

Over the next three years, about four billion KRW ($3.1 million) that Noul received from The RIGHT Foundation will be used to support global clinical studies and cost-effectiveness analysis of the miLab™ Platform in Africa and Asia.

To ensure the credibility of the result, Noul will collaborate with global institutions and national malaria programmes such as PATH (Programme for Appropriate Technology in Health), Swiss TPH (Swiss Tropical and Public Health Institute), GIDC (Ghana Infectious Disease Center), MNMCP (Malawi National Malaria Control Programme) and University of Notre Dame in the US.

Noul and The RIGHT Foundation will conduct multi-country clinical studies to compare the diagnostic accuracy of the miLab™ with the result of the gold standard microscopic diagnosis and PCR analysis. Also, both parties will analyse the value and cost-effectiveness of the miLab™ Platform in the global healthcare market, and accelerate public market entry through local product registration.

Noul's miLab™ diagnostic platform is an all-in-one blood diagnosis platform that combines cartridge, solid-based next-generation staining and immunostaining (NGSI) stamping technology, and embedded artificial intelligence. miLab™ is used at Korea Disease Control and Prevention Agency, Carlos III Health Institute in Spain, the National Center for Malaria & Vector Control in United Arab Emirate and Boston Chldren's Hospital in the US.